LEVETIRACETAM- levetiracetam injection, solution
Athenex Pharmaceutical Division, LLC.
Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.
Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults with juvenile myoclonic epilepsy.
Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy.
Levetiracetam in Sodium Chloride Injection is an antiepileptic drug indicated for adult patients (16 years and older) when oral administration is temporarily not feasible.
Levetiracetam in Sodium Chloride Injection is for intravenous use only. It is available in three different concentrations single-dose 100 mL bag, each containing a different total dosage of levetiracetam: 500 mg (5 mg per mL), 1,000 mg (10 mg per mL), or 1,500 mg (15 mg per mL).
A single-dose 100 mL bag should be administered intravenously over a 15-minute IV infusion period.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Levetiracetam in Sodium Chloride Injection should not be further diluted prior to use. Any unused portion of the Levetiracetam in Sodium Chloride Injection contents should be discarded.
Levetiracetam can be initiated with either intravenous or oral administration.
In clinical trials of oral levetiracetam, daily doses of 1,000 mg, 2,000 mg, and 3,000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)] , a consistent increase in response with increased dose has not been shown.
Treatment should be initiated with a daily dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1,000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3,000 mg. Doses greater than 3,000 mg/day have been used in open-label studies with levetiracetam tablets for periods of 6 months and longer. There is no evidence that doses greater than 3,000 mg/day confer additional benefit.
Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy
Treatment should be initiated with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been studied.
Primary Generalized Tonic-Clonic Seizures
Treatment should be initiated with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been adequately studied.
When switching from oral levetiracetam, the initial total daily intravenous dosage of levetiracetam should be equivalent to the total daily dosage and frequency of oral levetiracetam.
At the end of the intravenous treatment period, the patient may be switched to levetiracetam oral administration at the equivalent daily dosage and frequency of the intravenous administration.
Levetiracetam dosing must be individualized according to the patient’s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. To use this dosing table, an estimate of the patient’s creatinine clearance (CLcr) in mL/min is needed.
1 Following dialysis, a 250 to 500 mg supplemental dose is recommended.
|Group||Creatinine Clearance (mL/min)||Dosage (mg)||Frequency|
|Normal||> 80||500 to 1,500||Every 12 hours|
|Mild||50 to 80||500 to 1,000||Every 12 hours|
|Moderate||30 to 50||250 to 750||Every 12 hours|
|Severe||< 30||250 to 500||Every 12 hours|
|ESRD patients using dialysis||—-||500 to 1,000||1 Every 24 hours|
For doses (e.g., 250 mg and 750 mg) not achievable with the available product strengths, using aseptic technique, withdraw the appropriate dose (see Table 1) from an intact commercial bag and place the measured dose in a separate empty, sterile infusion bag. Administer the prepared dose by intravenous infusion over a period of 15 minutes. The unused portion of the original commercial bag must be discarded. Do not store or reuse.
Levetiracetam in Sodium Chloride Injection is found to be physically compatible and chemically stable for at least 24 hours when mixed with lorazepam, diazepam, and valproate sodium and stored at controlled room temperature 15° to 30°C (59° to 86°F).
There are no data to support the physical compatibility of levetiracetam injection with antiepileptic drugs that are not listed above.
Avoid abrupt withdrawal from levetiracetam in order to reduce the risk of increased seizure frequency and status epilepticus [see Warnings and Precautions (5.6)].
Single-dose 100 mL bags of Levetiracetam in Sodium Chloride Injection, a clear, colorless solution, which contain:
- 500 mg Levetiracetam in 0.82% sodium chloride injection (500 mg per 100 mL)
- 1,000 mg Levetiracetam in 0.75% sodium chloride injection (1,000 mg per 100 mL)
- 1,500 mg Levetiracetam in 0.54% sodium chloride injection (1,500 mg per 100 mL)
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.